Aurobindo Unit CuraTeQ Gets UK Approval for Breast Cancer Biosimilar

CuraTeQ Biologics, a step-down subsidiary of Aurobindo Pharma, has received marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency for Dazublys, its trastuzumab biosimilar for the treatment of breast cancer in adults.

The approval follows a similar clearance from the European Commission earlier this month. This is CuraTeQ’s fourth biosimilar approval in the UK after Bevqolva in December, Zefylti in May, and Dyrupeg in June, all of which are also cleared in the European Union.

The company has a pipeline of 14 biosimilars and aims to launch at least 10 by 2030.